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Objectives: we investigated the therapeutic effect of angioplasty with local drug delivery (LDD) of the wall-accumulating
NO-donor molsidomine (M) in the superficial femoral arteries (SFA) of atherosclerotic swine.
Materials and methods: atherosclerotic Pietrin swines (n=14) underwent PTA-LDD-M (4 mg/2 ml) vs contralateral
PTA-LDD-Placebo in the SFA using a channelled balloon angioplasty catheter. Invasive and colour Doppler energy
(CDE) assessments of haemodynamics and wall mechanics were performed at 24 h (n=4) and 5 months (n=10). Immuno-
histolabelling of cell proliferation and histomorphometry were serially performed in perfusion fixed SFA samples.
Results: at 24 h, PCNA-positive nuclei revealed 33±14 and 12±3 proliferating cells/mm2 at placebo and molsidomine
PTA-LDD sites, respectively (p<0.001). At 5 months, PTA-LDD-M vessels, compared with PTA-LDD-P, had increased
compliance (66±9 vs 11±4 ml/mmHg) and lowered impedance (0.11±0.05 vs 0.45±0.14 mmHg/ml min−1) (p<0.05).
CDE revealed low, middle and high velocity peaks at 7.5, 20 and 35, and 8, 15 and 22 cm s−1 in systolic and diastolic
flows, respectively; and PTA-LDD-M prevented emergence of restenosis-associated increases in low blood velocities
(p<0.01). PTA-LDD-M inhibited restenotic intimal thickening and medial thinning which decreased mean lumenal
diameter in placebo-treated (2.6±0.3) as compared to molsidomine-treated (3.4±0.3 mm) vessels (p<0.05).
Conclusions: in the atherosclerotic porcine SFA model, PTA-LDD with molsidomine consistently improved haemodynamic
wall mechanics, lowered cell proliferation and prevented late lumen loss observed with PTA-LDD with placebo.
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Introduction inhibit thrombosis,12,13 inhibit extra-cellular matrix
deposition7,14–16 and promote the maintenance of nor-
Following angioplasty in the superficial femoral artery mal, vascular smooth muscle function, and inhibit
(SFA), only 50% of patients show long-term symp- inflammation.11,14–18
tomatic improvement.1–3 Specifically, the clinical out- The sydnonimines, especially molsidomine, liberate
come appears to be dependent upon (i) haemodynamic NO leading to development of tolerance.19,20 They have
success and restoration of wall mechanics post-inter- no specific intramural binding properties,11 but when
vention, (ii) reactive and adaptive remodelling pro- coupled with the channelled balloon angioplasty cath-
cesses,2,4,5 and (iii) thrombo-embolic complications.2,4 eter, there appears21–24 capable of efficient, transmural
Atherosclerotic swine provide a good model of the drug delivery. Furthermore, this agent has a unique
human situation.6–9 Local drug delivery (LDD) is a property of accumulating in significant amounts
logical approach to post-angioplasty restenosis and within the heart muscle and arterial walls.25 In a por-
occlusion in the SFA.8–10 Specifically, nitric oxide (NO)- cine model we have previously reported that these
donors11 affect vascular tone and wall dynamics,11,12 compounds have a beneficial impact on restenosis
through effects on NO and vascular smooth muscle
cells.7,26–30
∗ Please address all correspondence to: P. H. Rolland, Laboratoire However, early attempts to demonstrate ex-d’He´modynamique et de Me´canique Cardiovasculaire, Faculte´ de
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sydnonimines at the time of PTA,31,32 continued or not
by oral administration of molsidomine, have yielded
promising results with the conclusions that both chem-
ical nature of the NO-donor and drug delivery device
must be optimised in order to yield the expected
anti-restenotic effect.26,32,33 The present study therefrom
investigate the haemodynamic and morphologic con-
sequences of molsidomine delivery with the chan-




The animals were handled in accordance with the
Guide for the Care and Use of Laboratory Animals
(National Research Council, Natl Acad Press, Wash-
ington, DC, U.S.A., 1996). For 6 months, 14 male Pietrin
pigs (40.9±4.2 kg at 6 months of age; Blossin SA,
Aubagne, France) were fed the Marseille atherogenic
diet which accelerates development of athero-
sclerosis.6,30,31 At 6 months, angioplasty with local drug
delivery (AP-LDD) was performed with molsidomine
and placebo in bilateral superficial femoral arteries
(SFA); and the animals were placed back on control
diet.30,31 Twenty-four hours (n=4) and 5 months (n=
10) after AP-LDD, animals were submitted to an-
giographic, haemodynamic, vascular wall rheologic
Fig. 1. Graph shows that cholesterol-related serum parameters wereand colour Doppler energy investigations. Vessels
increased in swines at time of AP-LDD (6 months, mean±s.d., n=were pressure fixed at physiologic condition and
14). Microphotograph illustrates that atherosclerotic lesions in the
sampled for histomorphological assessment.29 SFA contained a fibrous cap (FibC), a lipidic core (LpC) with focal
necrosis (nec) and media intimalisation (MedInt) with elastic laminae
disruption (red arrow) and reorientation and migration of smooth
muscle cells (black arrow).
Radiologic procedures and angioplasties
saphenous artery (ISA) branch and the popliteal-pos-
terior tibial arteries (PopA-postTA) bifurcation (Fig.All procedures were performed on anaesthetised
pigs28,29 in dorsal position with the lower legs folded 1). The pre-procedure lumenal diameter by using the
dimensional characteristics of the balloon. A 3 mindown thereby defining the radiologic posture. A digit-
ised subtraction angiographic Stenoscop system (Gen- inflation time at 10 atm was performed using a mixture
of saline and contrast medium (50:50, v/v) duringeral Electric Medical System, Minneapolis, U.S.A.) was
used for radiologic procedures with access through which molsidomine delivery was conducted by a 2 min
perfusion time at 1 ml/min, at 6 atm (60 and 10 ml,surgically isolated, right carotid artery (7F vascular
sheath, Cordis/J&J, Miami, FL, U.S.A.). No heparin Leveen Inflators, BSC-MediTech). Molsidomine (4 mg/
2 ml) and control saline solution (2 ml isotonic sodiumwas used. Routine angiograms were obtained from a
NightHawk angiographic catheter (5F, 100 cm, BSC- chloride solution containing dextran 60 – 6%, p/v and
glucose, 10%, p/v) in ampules were a kind gift fromMediTech, Watertown, MA, U.S.A.) advanced over
a glidex-coated hydrophilic 0.035 in guidewire (BSC- Dr Grewe (Hoechst, Taunus, Germany). The lumen
diameter of the SFAs was 5.4±0.3 mm (n=14), with aMediTech). The channelled balloon angioplasty cath-
eter (BSC-CB, 6×40 mm; Boston Scientific Corp, Na- 1.10–1.15:1 balloon/artery diameter ratio. The
sequence for local drug delivery involved AP-LDDtick, MA, U.S.A.) was advanced in between the internal
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using control saline in one SFA, randomly chosen; and
repeated AP-LDD using molsidomine in the opposite
SFA. Post-procedural angiograms and lumenal dia-
meter measurements were obtained as described
above. After surgical closure of puncture site and
wound, the pig was transferred to the postoperative
suite for recovery.
Haemodynamics and wall rheology in SFAs, echodoppler
From a local incision, SFA was carefully freed (without
apparent disruption of blood supply to the adventitia)
from the profunda femoralis branch down to the PopA-
postTA arteries bifurcation. Haemodynamics and wall
mechanics measurements29,34 were centred on AP-LDD
site and consisted of intravascular measurements of
pulsatile blood pressure with a 2F Mikro-Tip Catheter
pressure transducer SPR-249 (Millar Instruments, Inc.,
Houston, TX, U.S.A.). Pulsatile flow measurements
were carried out by using the T206 blood flow meter
(Transonic Systems, Inc., Ithaca, NY, U.S.A.) and ap-
propriate perivascular RB flowprobes. Pulsatile ex-
ternal diameter was assessed by using a facing pair
of ultrasonic probes (10 MHz) inserted within a silicone
clip-probe, and connected to 4-channels sono-
micrometer (Triton Technology Inc., San Diego, CA,
U.S.A.).
Systolic and diastolic blood flow velocities at the
PTA site (as a frame fixed in depth and centred length
in between ISA branch and PopA-PostTA bifurcation)
were further non-invasively investigated by Colour Fig. 2. Angiograms show that luminal narrowing was observed in
Doppler Energy (CDE) measurements of the lon- the native distal SFA (a). The angioplasty site was delimited by the
internal saphenous artery (ISA) embranchment, proximally, andgitudinal density profile of velocities (i.e. a range from
by the popliteal artery (PopA) – posterior tibial artery (postTA)0 to 50 cm/s) along a middle-vessel line (i.e. to estimate bifurcation, distally. Low-pressure channel balloon inflation dis-
velocities found in the middle of the vessel). Having played the stenotic lesion (b, arrow). Lipiodol infusion shows the
circumferential infusion pattern (c, arrow). Postprocedure an-a colour signal independent of the angular Doppler
giogram (d) of the native SFA in (a) illustrate the efficacy of theshots, a lower signal/noise ratio than velocity Doppler angioplasty with the channel balloon. At 5 months in the same
and being devoid of spectral foldings (i.e. which led animal, control angiograms show the beneficial angiographic results
in the molsidomine-treated SFA (e), as compared to the placebo-to a high accuracy and sensitivity for the blood flows
treated SFA (f).in the low range), CDE signal intensity was proved to
be observer independent and influenced by fluid flow
velocity, only.35,36 At the same depth and instrument probe) displaying the varying pulsatile flow velocities
(see Fig. 3). From the video recordings, Adobe Premi-settings (as is the case in the study), the CDE signal
was found to be proportional to the returning signal ere software (Adobe Systems Inc.) was used to digitise,
extract and convert (into a 256 grey levels scale) thestrength and to provide high-resolution cross-sectional
display of the vessel which can be stored on video tape individual systolic and diastolic images along the ori-
ginal cardiac cycles triggered by the R-wave. Theor numerised and subsequently subjected to computer
analysis for extracting flow velocities from the scale SAMBA 2005 automatic scanning image analyser
(TITN-Alcatel, Grenoble, France)6,7,27,30 enables drawinggiven by the instrument.35,36 With standardised ap-
plication, CDE was recorded in SFAs under constant a mid-vessel line along the entire segment to maintain
identical length in systolic and diastolic images. Theamplifying magnitude for 15 cardiac cycles with an
HDI 5000 ATL echodoppler instrument (7.5 MHz optical density (OD) profiles were recorded pixel by
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Fig. 3. Graphs display the density count analysis at the location of data values (n=10, confidence intervals from 8 to 16% are not shown)
of mid-vessel distribution of blood velocities measured by colour doppler energy (illustrated in insert) in the middle of the SFA (positioned
as a white line), 5 months after angioplasty with local delivery of placebo (dashed line) or molsidomine (dark line), both in systolic (B,
D) and diastolic (A,C) situations, respectively. Note that the drug reduced the angioplasty-induced enlargement in the range of CDE
velocities by shifting the lowest velocities to the highest range values.
pixel along the line and further converted to blood elastic fibres, or processed for immunohistological
PCNA labelling.28,32 Morphometric analysis was per-velocities according to the instrument-dependent col-
formed under ×15–400 magnification light micro-our map, treated accordingly. Finally the blood velocity
scopy, using an automatic videoanalyser, SAMBA 2005values in individual cycles were averaged in the sys-
(TITN-Alcatel, Grenoble, France).6,7,27,30 Densitometrytolic and diastolic phases for both placebo or mol-
analysis of PCNA staining was computerised as thesidomine-treated legs; and profiles of velocities in the
number of labelled nuclei per unit surface. In theaveraged cycles were established using density count
lesional sites, morphometric analysis of the arterialtechnique in Systat 9.0 statistical software (SPSS Inc.,
section geometry consisted of (i) delineating on theChicago, IL, U.S.A.).
computer screen, the boundaries of the lumen, intima-
media and media-adventitia junctions, (ii) centring 24
radial pairs of 2 orthogonal diameters on the arterial
Morphometry and immunocytochemistry section, and (iii) measurement of 96 triplets of radial
lumen, intima and media thickness. In each sample at
Immediately after haemodynamics measurements, the the lesional site, the distribution of the morphometric
animals were euthanised (midazolam 15 mg and chlor- data were further submitted to density count analysis,
promazine 25 mg in KCl 15% (p/v), 20 ml, i.v. bolus) and further averaged to yield the final density count
and serial pathologic slides, orthogonally sectioned profile per leg and per animal.
(6 m) were obtained after in situ fixation with 10%
formalin under a constant 120 mmHg perfusing pres- Statistical analysis
sure.28,32 Deparaffined slides were stained with Mas-
son’s trichrome for general observation or with the Data treatment and statistical analyses were performed
by using Systat 9.0 software (SPSS Inc., Chicago, IL,Lillie and Fullmer’s orceine for specific staining of
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U.S.A.). Results are expressed as mean±standard de- mm2, at the AP-LDD with placebo and molsidomine,
respectively (p<0.001), which indicate that, 24 h afterviation (SD). In constructing and analysing the blood
velocities and vessel dimensions, multicates in each angioplasty, molsidomine delivery maintained cell
proliferation state to baseline level of 9±2 stainedleg and in each subject were averaged to yield an
individual value or profile subjected to dot density nuclei/mm2.27 Finally, local delivery of molsidomine
as compared to placebo delivery at the time of an-count analysis along the horizontal data scale at the
location of data values. Statistical analysis of the meas- gioplasty induced parallel magnification of both sys-
tolic (374±54 vs 135±34 ml/min) and diastolicures for molsidomine-treated arterial sites vs controls
was performed by using the Kruskal–Wallis test (i.e. (176±51 vs 78±13 ml/min) flows with increased
mean blood flow (374±54 vs 135±35 ml/min)the non-parametric analogue of a one-way analysis of
variance), which reduced to the Mann–Whitney test (p<0.05), due to increased compliance in the treated
sites (90±10 vs 27±5 ml/mmHg) (p<0.05), re-(i.e. the non-parametric analogue of the two-sample t-
test) when there are only two groups. spectively.
Angioplasty with LDD, mid-term results at 5 monthsResults
As they were in pre-procedure angiograms, luminalAtherosclerosis model
diameter narrowing was observed in some of the
placebo-treated sites (Fig. 2). The early vasodilatoryThe animals remained healthy throughout the pro-
changes in the haemodynamics and wall mechanicsgram period. At 6 months, the atherogenic diet in-
induced by molsidomine delivery during angioplastycreased cholesterol-related serum parameters in the
persisted at 5 months, as compared to the placeboswines (Fig. 1) without significant additional changes
sites: both maximum (270±98 vs 171±82 ml/min)in the serum biochemistry.6,27 the type IIa hy-
and minimum (85±57 vs 57±14 ml/min) flows hadpercholesterolemia-induced atherosclerotic lesions
parallel magnification due to increased compliancewere detectable under gross pathologic examination
(66±9 vs 11±4 ml/mmHg) and lowered entry im-of the SFA proximal to the angioplasty site at 24 h
pedance (0.11±0.05 vs 0.45±0.10 mmHg/ml min−1)(Fig. 1). These lesions had the common pathological
(p<0.05), which also indicate the worsening situationappearance relevant to the reported assessment of
at the placebo-treated site.human lesions.6,7,27 Upon examination of the pre-
In dot histograms (Fig. 3) showing the density (withangioplasty arteriograms, angiographic reduction in
a unique symbol as the relative concentration of dataluminal diameter was observed (Fig. 2a) in some
points in intervals) of every velocity across the rangeinstances but not generally influencing the average
of the distribution, non-invasive haemodynamic in-diameter.
vestigations in the SFA at 5 months demonstrated that,
in SFAs following angioplasty with placebo delivery,
blood flow elicited a 3 peak-shaped distribution of
velocities in both the systolic and diastolic situationsAngioplasty with LDD
due to the emergence of a lowest velocity group. By
definition, low, middle and high velocities peaked atThe BSC-CB device was placed and inflated in the SFA
in all cases (Fig. 2a). No acute complication occurred 7.5, 20 and 35 cm s−1 and 8, 15 and 22 cm s−1 in the
systolic and diastolic flows, respectively. The resultsduring intraSFA insertion, deployment, liquid solution
delivery or retrieval of the balloon along the guidewire. show that both diastolic and systolic flows were in-
creased at the molsidomine delivery sites, due to aThe average SFA lumen diameter at the dilatation site
was similar in both SFAs before angioplasty: shift of the lowest velocities to the higher range of the
spectrum. Specifically, the density counts in the systolic(5.5±0.2 mm; n=28 vessels). At 24 h (n=4), the SFA
luminal diameter was 5.7±0.2 mm (n=4) and peaks of velocity were 9.4±1.1 vs 0.7±0.1∗, 40.2±3.9
vs 28.8±3.1, and 48.9±5.4 vs 103.2±12.1 counts for5.9±0.3 mm (n=4) at the AP-LDD with placebo and
molsidomine, respectively, which shows that equi- the placebo vs molsidomine-treated angioplasty sites
(∗: p<0.01), respectively; and similarly the densityvalent angioplasty was performed at both sites. In the
arterial wall at 24 h, the number of PCNA-positive counts for the diastolic flows, the density counts were
19.1±3.0 vs 8.7±1.6∗, 93.8±9.6 vs 99.2±7.3, andnuclei, i.e. the proliferating nuclei, was found to be
33±14 stained nuclei/mm2 and 12±3 stained nuclei/ 37.5±5.2 vs 139.4±11.2 counts for the placebo vs
Eur J Vasc Endovasc Surg Vol 23, March 2002
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1.10±0.12 mm in the molsidomine-treated site,
whereas the placebo-treated site had a dramatically
enlarged peak centred at 0.85±0.24 mm (p<0.001).
Finally, the mean lumenal radius in the placebo-treated
and molsidomine-treated PTA sites were 2.6±0.34
and 3.4±0.31 mm, respectively (p<0.05). The results
indicate that PTA-LDD-M prevented the increases in
both the intima thickness and intima-media ratio, as
well as the media thinning. As a consequence, the
lumenal radius was lowered by 24% in the placebo-
treated arm as compared to the treated arm (p<0.05).
Discussion
The main result of the present study is that local
delivery of the aqueous perfusate of NO-donor parent
compound molsidomine at the time of angioplasty
Fig. 4. Graphs display the morphometry of the lesional site in the with the channelled balloon catheter led to late lumen
SFA 5 months after angioplasty with local delivery of placebo preservation superior to those of PTA-LDD with
(dashed line) (insert A and B) or molsidomine (dark line) (insert
placebo, as well as to beneficial post-angioplastyC), as the density count analysis at the location of data values
(n=10, confidence intervals from 7 to 14% are not shown) of changes in haemodynamics and wall mechanics, and to
computerised thickness of the media (a) and intima (b) and the inhibition of proliferative response in the SFA arterial
radius length (c) along 96 radiant radii per slide. Inserts are orceine-
walls. The data further demonstrated that local de-stained slides (×250).
livery of molsidomine in the porcine SFA minimised
occurrence of (i) a low-velocity pattern in blood flow,
known to favour development of arterial lesions,37,38molsidomine-treated angioplasty sites (∗: p<0.01), re-
spectively. Therefrom, AP-LDD with molsidomine cre- and (ii) a focalised intimal thickening and converse
media thinning with an increased intima/media ratio,ated a homogeneous blood flow distribution and the
treatment did not increase the blood flow velocities thereby leading to a larger lumenal diameter in treated
vessels. Finally, the safety of PTA procedure is sup-outside of the spectrum range in the placebo-treated
SFAs. ported by early angiographic results which did not
show any significant arterial damages or differencesPathologic examinations of the PTA sites in the
explanted SFA segments at 5 months revealed non- between LDD with placebo or molsidomine.
Haemodynamics and wall mechanics at endo-lipidic fibrosclerotic and cell proliferations and al-
terations of the elastic structures, histologic char- vascular intervention play a significant role in the
location, development, progression of atherosclerosis,acteristics of restenotic processes with (Fig. 4).
Morphometric analysis of the lesions identified the early and late restenosis, as well as the propensity
for subacute thrombosis.37,38 Consequently, in the SFArestenosis-associated intimal thickening and converse
medial thinning; and increased intima-media ratio and it is established that return to normal ankle-brachial
pressure index (ABPI >0.9 at 24 h) is a stronglowered lumenal diameter (Fig. 4). Specifically, intimal
thickness in the placebo-treated site was characterised indicator of a favourable long-term prognosis after
angioplasty.1 By investigating the vessel complianceby the emergence of a density peak at 0.75±0.12 mm
and an increased density peak at 0.48±0.14 mm which estimates how the elastic wall reacts in
response to the haemodynamic forces, as well as(p<0.05 as compared with the molsidomine-treated
site); whereas the molsidomine-treated sites had a how the vessel recoils to further propel blood
flow along the vasculature,39 we have shown thathomogeneous peak (at 0.21 mm) in intimal thickness.
Similarly, the intima-media ratio evidenced two dens- molsidomine delivery led to a persistent increase in
the SFA vascular strain (i.e. changes in volume dueity peaks (centred at 0.28 (80%) and 0.60 (20%)) in the
placebo-treated sites, whereas a single density peak at to wall circumferential elongation) in response to
the stress (i.e. distending blood pressure wave). This0.16 was characteristic of the intima/media ratio in
the molsidomine-treated site. The medial thickness in turn resulted in decreased entry impedance and
increased blood flow with constant pulse flow. Thepeak was uniformly shaped and centred at
Eur J Vasc Endovasc Surg Vol 23, March 2002
P. H. Rolland et al.232
latter is further demonstrated by colour Doppler Future directions/next steps
energy investigations revealing that PTA-LDD-M
prevented emergence of restenosis-associated low We report here the mid-term therapeutic efficacy of
local molsidomine delivery at the time of angioplastyblood velocities. As mechanical forces play an im-
portant role in the modification of the vascular under the experimental conditions of pre-existing ath-
erosclerotic lesions in the porcine SFA. The ex-structure, it is presently accepted that the vessel
remodels its geometry, structure and composition in perimental protocol was based upon technically
challenging solutions for simultaneous local drug de-response to angioplasty in a way to produce a more
homogeneous stress distribution from the inner wall livery and angioplasty derived to address the key
determinants in SFA restenosis. The design of theto the outer wall.40 It is also acknowledged that
these remodelling targets may be reached at the channelled angioplasty balloon enables delivery of
adequate quantities of drug to the vessel wall withoutexpense of pathological changes in wall metabolism
and mechanical properties.41 The residual strains, either injuring the wall or compromising flow. The
commercially available, aqueous i.v. perfusate allowswhich determine the stress distribution through the
artery wall following geometrical changes,40 are penetration, retention and convection of the 4 mg ad-
ministered drug by using the increased hydraulic con-concentrated in the inner, intimal layers, which
contain more elastin than the collagenous outer ductance of atherosclerosis. The optimisation of the
NO-donor molecule, which is retained for severallayers which contribute little to the residual strains.
From these, the inner layers remodel themselves in days and continuously released, avoids the risk of cell
toxicity due to a concentrated localised presence ofresponse to stress concentration by developing more
compressive residual strains than the outer layers.41 NO within the vessel wall. Additionally, NO, as the
active agent, possesses the “multi-purpose” phar-By preserving the integrity of the internal elastic
laminae, molsidomine delivery obviously favours the macologic properties addressing the “multi-com-
ponent” compensatory responses of the restenoticlatter processes. On the other hand, changes in
arterial compliance, detectable as early as at 24 h after development in the atherosclerotic SFA.
Finally, caution has to be taken in extrapolating themolsidomine delivery, may be due to a synergistic
combination of adaptive structural changes and of present results because of the reported disparity laying
between animal model data and clinical trial ex-relaxation in arterial smooth muscle tone. This would
in turn alter the relative loading of collagen and perience.16 The efficacy for the present protocol es-
tablished for angioplasty with local molsidomineelastin fibres by transferring stress from the less
extensive collagen fibres to elastin.42 The net result delivery will be examined in a controlled clinical trial
as the next step.of these structural adaptations is that intimal layers
and endothelial cells are in a new dynamic equi-
librium with their ambient fluid and solid mechanical
environment.43 The observation of beneficial, thera-
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